Antrin motexafin lutetium: Phase I

Preliminary results from 39 patients in PCYC's dose-escalation U.S. Phase I trial, 35 of whom received light activation of the compound, showed that 0.05-4 mg/kg doses of Antrin administered intravenously 18-24 hours before balloon angioplasty resulted in no instances of coronary artery bypass, death, stroke, myocardial infarction, target lesion revascularization or stent thrombosis after 30 days, and no dose-limiting toxicities. Data were presented at the American Heart Association meeting in New Orleans. The trial is expected to enroll a total of 50-75 patients. ...